These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 36404519)
1. Correlation of Engraftment and Time from Melphalan Administration to Stem Cell Infusion. Shuman K; Palmer S; Anders B; Moore D; Ptachcinski J; Grgic T; Alexander M; Hill L; Sung AD; Armistead PM; Kennedy L; Shaw JR Transplant Cell Ther; 2023 Jan; 29(1):36.e1-36.e5. PubMed ID: 36404519 [TBL] [Abstract][Full Text] [Related]
2. Melphalan on day -1 versus day -2 in patients with plasma cell disorders undergoing autologous stem cell transplant. Watson AN; Shah SA; Shalhoub SD; Piedra KM; Komanduri KV; Kwon D; Pereira DL J Oncol Pharm Pract; 2023 Sep; 29(6):1398-1403. PubMed ID: 36245321 [TBL] [Abstract][Full Text] [Related]
3. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation. Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672 [TBL] [Abstract][Full Text] [Related]
4. Differences in engraftment with day-1 compared with day-2 melphalan prior to stem cell infusion in myeloma patients receiving autologous stem cell transplant. Al Saleh AS; Sidiqi MH; Lee J; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Skaer CA; Wittwer SK; Wolf RC; Hogan WJ; Kumar SK; Jacob E; Gertz MA Bone Marrow Transplant; 2020 Nov; 55(11):2132-2137. PubMed ID: 32358546 [TBL] [Abstract][Full Text] [Related]
5. Impact of melphalan day -1 vs day -2 on outcomes after autologous stem cell transplant for multiple myeloma. Merino A; Shanley R; Rashid F; Langer J; Dolan M; Tu S; Jurdi NE; Rogosheske J; Hanna K; DeFor T; Janakiram M; Weisdorf D Front Immunol; 2024; 15():1310752. PubMed ID: 38504993 [TBL] [Abstract][Full Text] [Related]
6. Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Sivakumar A; Bryson EB; Hall KH; Maples KT; Goyal S; Joseph NS; Hofmeister CC; Kaufman JL; Lonial S; Nooka AK; Harvey RD Pharmacotherapy; 2022 Mar; 42(3):233-240. PubMed ID: 35122287 [TBL] [Abstract][Full Text] [Related]
14. Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation. Kowalski KE; Wheeler SE; Adams CB; Voils SA; Richards AI J Oncol Pharm Pract; 2022 Mar; 28(2):274-281. PubMed ID: 33435822 [TBL] [Abstract][Full Text] [Related]
15. The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning. Ursu SG; Maples S; Williams KJ; Patrus G; Samhouri Y; Fazal S; Mewawalla P; Sadashiv S J Hematol; 2023 Oct; 12(5):201-207. PubMed ID: 37936977 [TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Propylene Glycol-Free Melphalan Combined with Carmustine, Etoposide, and Cytarabine for Myeloablative Conditioning in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation. Cashen AF; Fletcher T; Ceriotti C; Gao F; Ghobadi A; Vij R; Stockerl-Goldstein K; DiPersio J; Abboud C Biol Blood Marrow Transplant; 2016 Dec; 22(12):2155-2158. PubMed ID: 27575541 [TBL] [Abstract][Full Text] [Related]
17. [High dose melphalan (HDM) is superior to cyclophosphamide plus etoposide and busulfan (CVB) as the conditioning regimen in autologous stem cell transplantation for multiple myeloma]. Gu JL; Li J; Liu JR; Zou WY; Huang BH; Zheng D; Wang HH Zhonghua Xue Ye Xue Za Zhi; 2019 Sep; 40(9):732-737. PubMed ID: 31648473 [No Abstract] [Full Text] [Related]
18. CD34+ cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin (CTCb) with PBPC support in metastatic breast cancer. Papadopoulos KP; Ayello J; Reiss RF; Troxel A; Kaufman E; Vahdat LT; Antman KH; Hesdorffer CS J Hematother Stem Cell Res; 1999 Aug; 8(4):357-63. PubMed ID: 10634173 [TBL] [Abstract][Full Text] [Related]